AJDRAJNR - American Journal of Neuroradiology

This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ostrov, S. G.
Right arrow Articles by Altman, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ostrov, S. G.
Right arrow Articles by Altman, R. D.

American Journal of Neuroradiology, Vol 3, Issue 1 21-23, Copyright © 1982 by American Society of Neuroradiology


ARTICLES

Cerebral atrophy in systemic lupus erythematosus: steroid- or disease- induced phenomenon?

SG Ostrov, RM Quencer, NB Gaylis and RD Altman

Thirty-two patients with systemic lupus erythematosus were evaluated clinically and with computed tomography in order to determine whether the occurrence of cerebral atrophy in systemic lupus erythematosus was due to the steroid therapy or the cerebral manifestations of the disease itself. Of these patients, 14 had central nervous system manifestations of the disease (lupus cerebritis) and 12 of the 14 were on long-term steroid therapy. Eighteen patients had no clinical evidence of lupus cerebritis and all were on long-term steroids. Of the 14 lupus cerebritis patients, 10 showed moderate cerebral atrophy, four minimal atrophy, and none were normal. Of the 18 patients without lupus cerebritis, none had moderate atrophy, six (33%) showed minimal atrophy, and 12 (67%) had normal CT scans. This data suggest that it is the lupus cerebritis rather than the steroid therapy that is responsible for the moderate cerebral atrophy. In patients suspected of lupus cerebritis, steroids should not be withheld because of concern for steroid-induced atrophy. Rather, the dose may need to be increased.


This article has been cited by other articles:


Home page
Am. J. Neuroradiol.Home page
S. C.A. Steens, G. M. Steup-Beekman, G. P.Th. Bosma, F. Admiraal-Behloul, H. Olofsen, J. Doornbos, T. W.J. Huizinga, and M. A. van Buchem
The Effect of Corticosteroid Medication on Quantitative MR Parameters of the Brain
AJNR Am. J. Neuroradiol., November 1, 2005; 26(10): 2475 - 2480.
[Abstract] [Full Text] [PDF]


Home page
Ann Rheum DisHome page
C C Mok, A Mak, and E Y K Tsui
Shrinking central nervous system in systemic lupus erythematosus
Ann Rheum Dis, May 1, 2004; 63(5): 603 - 604.
[Full Text]


Home page
Mult SclerHome page
E L. Hoogervorst, C H Polman, and F Barkhof
Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone
Multiple Sclerosis, October 1, 2002; 8(5): 415 - 419.
[Abstract] [PDF]


Home page
Am. J. Neuroradiol.Home page
A. Oatridge, A. Holdcroft, N. Saeed, J. V. Hajnal, B. K. Puri, L. Fusi, and G. M. Bydder
Change in Brain Size during and after Pregnancy: Study in Healthy Women and Women with Preeclampsia
AJNR Am. J. Neuroradiol., January 1, 2002; 23(1): 19 - 26.
[Abstract] [Full Text] [PDF]